Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Caribou Biosciences, Inc. (CRBU : NSDQ)
 
 • Company Description   
Caribou Biosciences Inc. is a clinical-stage CRISPR genome-editing biopharmaceutical company. It involved in developing a pipeline of genome-edited, off-the-shelf CAR-T and CAR-NK cell therapies for the treatment of both hematologic malignancies and solid tumors. Caribou Biosciences Inc. is based in BERKELEY, Calif.

Number of Employees: 147

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.80 Daily Weekly Monthly
20 Day Moving Average: 689,180 shares
Shares Outstanding: 93.12 (millions)
Market Capitalization: $167.62 (millions)
Beta: 2.54
52 Week High: $3.00
52 Week Low: $0.66
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -10.00% -11.58%
12 Week 40.63% 27.74%
Year To Date 13.21% 7.25%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
2929 7TH STREET SUITE 105
-
BERKELEY,CA 94710
USA
ph: 510-982-6030
fax: -
investor.relations@cariboubio.com http://www.cariboubio.com
 
 • General Corporate Information   
Officers
Rachel E. Haurwitz - Chief Executive Officer; President
Sriram Ryali - Chief Financial Officer
Scott Braunstein - Director
Andrew Guggenhime - Director
Dara Richardson-Heron - Director

Peer Information
Caribou Biosciences, Inc. (CORR.)
Caribou Biosciences, Inc. (RSPI)
Caribou Biosciences, Inc. (CGXP)
Caribou Biosciences, Inc. (BGEN)
Caribou Biosciences, Inc. (GTBP)
Caribou Biosciences, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 142038108
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 06/01/25
Next Expected EPS Date: 11/05/25
Share - Related Items
Shares Outstanding: 93.12
Most Recent Split Date: (:1)
Beta: 2.54
Market Capitalization: $167.62 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.35 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.49 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: 1.85% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 11/05/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.01
Price/Cash Flow: -
Price / Sales: 18.38
EPS Growth
vs. Year Ago Period: 16.67%
vs. Previous Quarter: 18.60%
Sales Growth
vs. Year Ago Period: -23.01%
vs. Previous Quarter: 13.34%
ROE
06/30/25 - -62.35
03/31/25 - -55.70
12/31/24 - -50.21
ROA
06/30/25 - -49.65
03/31/25 - -45.35
12/31/24 - -41.49
Current Ratio
06/30/25 - 6.66
03/31/25 - 7.63
12/31/24 - 7.16
Quick Ratio
06/30/25 - 6.66
03/31/25 - 7.63
12/31/24 - 7.16
Operating Margin
06/30/25 - -1,568.03
03/31/25 - -1,490.84
12/31/24 - -1,491.94
Net Margin
06/30/25 - -1,800.93
03/31/25 - -1,490.84
12/31/24 - -1,491.94
Pre-Tax Margin
06/30/25 - -1,801.03
03/31/25 - -1,490.94
12/31/24 - -1,492.04
Book Value
06/30/25 - 1.79
03/31/25 - 2.34
12/31/24 - 2.79
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - 0.00
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - 0.00
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©